FUNDUSCEIN-25 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Funduscein-25, and what generic alternatives are available?
Funduscein-25 is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in FUNDUSCEIN-25 is fluorescein sodium. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluorescein sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Funduscein-25
A generic version of FUNDUSCEIN-25 was approved as fluorescein sodium by NEXUS PHARMS on September 25th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FUNDUSCEIN-25?
- What are the global sales for FUNDUSCEIN-25?
- What is Average Wholesale Price for FUNDUSCEIN-25?
Summary for FUNDUSCEIN-25
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 83 |
| Patent Applications: | 1,302 |
| DailyMed Link: | FUNDUSCEIN-25 at DailyMed |
US Patents and Regulatory Information for FUNDUSCEIN-25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | FUNDUSCEIN-25 | fluorescein sodium | INJECTABLE;INJECTION | 017869-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
